SOAR Supporting Outcomes and Advancing Research in Dup15q Syndrome 5

**At this time, the SOAR study has reached capacity for conference participation. However, there still may be opportunities for research participation at the family conference due to cancellations or addition of other opportunities. If you would like to be placed on a waitlist for research participation at the conference, please fill out the interest form.**

The Dup15q Alliance is thrilled to partner with Dr. Jeste and Dr. DiStefano on a Natural History Study in Dup15q syndrome. This study is an opportunity for us to collect the Natural History data we need now for potential Dup15q Clinical Trials that could start in the next few years.

 This study will involve meeting with your child, aged 2-18, and you as the caregiver for an interview and to complete some surveys. The aim is to document the behavioral and clinical features of Dup15q syndrome, track how these behaviors change over the course of one year, and identify the most effective measures for future clinical trials, both in-person and remote.

Are you interested in learning more?

Interest Form: https://forms.office.com/r/yEUMZYKTES

Webinarhttps://youtu.be/1nvY_UAXJ54?si=1fGROBWlWg7K9wHc

Website: SOAR Study – Supporting Outcomes and Advancing Research in Dup15q syndrome – The KINDD Laboratory | CHLA

 

Related Posts

FDA Issues Recall On Clonazepam Orally Disintegrating Tablets

FDA Issues Recall On Clonazepam Orally Disintegrating Tablets

The Dup15q Alliance is aware of the recent release by the FDA regarding Clonazepam Orally Disintegrating Tablets USP by Endo USA due to potential product carton strength mislabeling. Ongoing investigation identified the possibility that the affected clonazepam product...

Recall – Vigabatrin for Oral Solution USP

Recall – Vigabatrin for Oral Solution USP

TOPIC: Vigabatrin for Oral Solution USP, 500 mg by InvaGen Pharmaceuticals: Recall - Due to Leaking Sachets AUDIENCE: Patient, Health Professional, Pharmacy, Pediatric, Neurology ISSUE: InvaGen Pharmaceuticals is recalling one lot, NB301030, of Vigabatrin for Oral...

FDA Warns of Rare but Serious Drug Reaction

FDA Warns of Rare but Serious Drug Reaction

The Dup15q Alliance is aware of the recent release by the FDA regarding Keppra, Keppra XR, Elepsia XR, Spritam (levetiracetam) and Onfi, Sympazan (clobazam) warning about the risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). This adverse event is...